Management of Hyperleukocytosis

Area of Science:

• Hematology
• Oncology

Background:

• Hyperleukocytosis is associated with significant morbidity and mortality.
• Early mortality in hyperleukocytosis is often due to respiratory or central nervous system involvement and tumor lysis syndrome.
• Standard management protocols are essential for addressing acute hyperleukocytosis.

Purpose of the Study:

• To outline the critical components of managing acute hyperleukocytosis.
• To emphasize the importance of cytoreduction, supportive care, and tumor lysis prevention.
• To discuss the role and limitations of leukapheresis in hyperleukocytosis treatment.

Main Methods:

• Immediate initiation of hydration, alkalization, allopurinol, or urate oxidase.
• Careful administration of platelet and packed red blood cell transfusions based on specific counts and hemoglobin levels.
• Correction of coagulation abnormalities.
• Consideration of leukapheresis for metabolic derangements and viscosity reduction.
• Initiation of specific antileukemic therapy post-stabilization.

Main Results:

• Aggressive supportive care, including hydration and tumor lysis prophylaxis, is vital.
• Transfusion strategies must balance the risks of hemorrhage and increased blood viscosity.
• Leukapheresis offers potential benefits but has limitations in efficacy and availability.
• Early initiation of definitive antileukemic therapy is paramount once life-threatening complications are managed.

Conclusions:

• Comprehensive management of acute hyperleukocytosis involves a multi-faceted approach.
• Cytoreduction, supportive care, and timely antileukemic therapy are key to improving outcomes.
• Careful consideration of interventions like leukapheresis and blood product transfusions is necessary.